RxDoctor Payments Data

Joseph Roman, MD

Internal Medicine · College Station, TXNPI 1023166717

Payments from drug & device makers

$961in general payments, 2019–2025

Across 53 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$191
  • AstraZeneca$128
  • Pfizer$117
  • GSK$90
  • Astellas Pharma US Inc$76
  • Exact Sciences$75
  • plus $284 from 9 others

What the payments were for

  • Food & beverage$961100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$961 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$170,846
Medicare patients
398
Services billed
2,466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin100$116,354
OzempicSemaglutide78$104,867
TrulicityDulaglutide60$84,234
MounjaroTirzepatide46$80,051
FarxigaDapagliflozin Propanediol60$74,488
EliquisApixaban67$67,194
JanuviaSitagliptin Phosphate37$44,981
XareltoRivaroxaban19$26,314
MyrbetriqMirabegron32$25,939
Repatha SureclickEvolocumab27$22,573
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$19,310
JanumetSitagliptin Phos/Metformin Hcl11$17,084
Repatha SyringeEvolocumab18$15,044
Humalog Kwikpen U-200Insulin Lispro14$13,986
TradjentaLinagliptin13$12,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$22$164,284106 claims
Novo NordiskOzempic$191$104,86778 claims
AstraZenecaFarxiga, Symbicort$128$83,91185 claims
PfizerEliquis, Premarin$117$76,10585 claims
MerckJanuvia, Janumet, Belsomra$33$66,79259 claims
Astellas Pharma US IncMyrbetriq$76$25,93932 claims
GSKTrelegy Ellipta$90$19,31019 claims
AbbVieSynthroid$16$5,275127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in College Station

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →